agn 211745
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2004 (NCT00363714)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AANTISENSE INHIBITOR
VEGFA antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- agn211745
- agn 211745
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00395057 | Phase 2 | Jan 1, 2007 | Allergan |
| NCT00363714 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2004 | Allergan, Sirna Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 2 | 2 | 1 | 2004 |
| Sirna Therapeutics | For profit | 1 | 0 | 1 | 2004 |
2 organizations
Page 1 / 1